AVEO Pharmaceuticals Price to Sales Ratio 2010-2022 | AVEO

Historical PS ratio values for AVEO Pharmaceuticals (AVEO) over the last 10 years. The current P/S ratio for AVEO Pharmaceuticals as of May 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AVEO Pharmaceuticals P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-27 4.23 2.34
2022-03-31 5.59 $1.81 3.09
2021-12-31 4.69 $1.27 3.69
2021-09-30 6.18 $0.77 8.00
2021-06-30 6.59 $0.47 14.00
2021-03-31 7.32 $0.29 24.90
2020-12-31 5.77 $0.27 21.15
2020-09-30 5.94 $0.28 21.13
2020-06-30 5.15 $1.74 2.96
2020-03-31 3.62 $1.74 2.08
2019-12-31 6.24 $1.81 3.44
2019-09-30 8.45 $1.88 4.50
2019-06-30 6.73 $0.48 13.90
2019-03-31 8.20 $0.47 17.31
2018-12-31 16.00 $0.44 36.47
2018-09-30 33.10 $0.33 99.38
2018-06-30 22.60 $0.52 43.57
2018-03-31 29.00 $0.52 56.11
2017-12-31 27.90 $0.76 36.59
2017-09-30 36.50 $0.77 47.21
2017-06-30 22.20 $0.51 43.28
2017-03-31 5.90 $0.51 11.57
2016-12-31 5.40 $0.38 14.03
2016-09-30 8.90 $1.01 8.79
2016-06-30 9.61 $3.54 2.71
2016-03-31 9.20 $3.54 2.60
2015-12-31 12.60 $3.35 3.76
2015-09-30 12.10 $2.73 4.43
2015-06-30 17.40 $0.24 72.39
2015-03-31 14.50 $0.57 25.29
2014-12-31 8.40 $3.51 2.39
2014-09-30 11.10 $3.55 3.13
2014-06-30 18.30 $3.44 5.31
2014-03-31 14.95 $3.15 4.75
2013-12-31 18.30 $0.25 71.83
2013-09-30 20.60 $3.77 5.46
2013-06-30 25.00 $3.94 6.34
2013-03-31 73.50 $4.31 17.04
2012-12-31 80.50 $4.45 18.10
2012-09-30 104.10 $1.13 92.06
2012-06-30 121.60 $1.73 70.30
2012-03-31 124.10 $8.50 14.60
2011-12-31 172.00 $43.95 3.91
2011-09-30 153.90 $48.36 3.18
2011-06-30 206.10 $49.54 4.16
2011-03-31 133.20 $47.40 2.81
2010-12-31 146.20 $28.92 5.06
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.146B $0.042B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00